CT-Based Radiomic Signature as a Prognostic Factor in Stage IV ALK-Positive Non-small-cell Lung Cancer Treated With TKI Crizotinib: A Proof-of-Concept Study

Objectives: To identify a computed tomography (CT)-based radiomic signature for predicting progression-free survival (PFS) in stage IV anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitor (TKI) crizotinib. Materials and Methods:...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hailin, Zhang, Rui, Wang, Siwen, Fang, Mengjie, Zhu, Yongbei, Hu, Zhenhua, Dong, Di, Shi, Jingyun, Tian, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040202/
https://www.ncbi.nlm.nih.gov/pubmed/32133282
http://dx.doi.org/10.3389/fonc.2020.00057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040202/
https://www.ncbi.nlm.nih.gov/pubmed/32133282
http://dx.doi.org/10.3389/fonc.2020.00057

Ejemplares similares